.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EA05_Ponatinib.Ponatinib

Information

Ponatinib is an oral tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), particularly in cases with resistance or intolerance to prior tyrosine kinase inhibitor therapy, including cases with T315I mutation. It is currently approved and used in clinical practice.

Pharmacokinetics

Pharmacokinetic parameters reported in adult patients with hematologic malignancies (mainly CML and Ph+ ALL), after repeated oral administration of ponatinib at a daily dose of 45 mg. The population was comprised of both male and female subjects.

References

1. Hanley, MJ, et al., & Venkatakrishnan, K (2022). Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development. Journal of clinical pharmacology 62(4) 555–567. DOI:10.1002/jcph.1990 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34699069

2. Narasimhan, NI, et al., & Sonnichsen, D (2013). Effects of food on the pharmacokinetics of ponatinib in healthy subjects. Journal of clinical pharmacy and therapeutics 38(6) 440–444. DOI:10.1111/jcpt.12082 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23888935

3. Lau, C, et al., & Westerweel, PE (2024). Varying concentrations of tyrosine kinase inhibitors in chronic myeloid leukemia patients following bariatric surgery: a case series. Annals of hematology 103(11) 4765–4771. DOI:10.1007/s00277-024-05924-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39129028

Revisions

• 06/2025 initial generated model